Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2013 Feb 26;110(9):3214-5.
doi: 10.1073/pnas.1300822110. Epub 2013 Feb 14.

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease

Anthony H V Schapira  1 , Matthew E Gegg
Affiliations
Comment

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease

Anthony H V Schapira et al. Proc Natl Acad Sci U S A. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
The glucocerebrosidase/SNCA axis, potential targets for therapeutic intervention for PD. SNCA interacts with both wild-type (WT) and mutant (Mut) GCase, and modulation of this may serve to reduce SNCA concentrations and delay or reverse PD-related pathology. Strategies to increase lysosomal GCase or to decrease extralysosomal GCase–SNCA interactions would be anticipated to reduce SNCA concentrations. Chaperones, histone deacetylase inhibitors [HDACi), or increased expression of GCase by, for example, gene therapy (AAV-GBA) may be examples of such strategies.
See this image and copyright information in PMC

Comment on

References

    1. Sardi SP, et al. Augmenting CNS glucocerebrosidase activity as a therapeutic strategy for parkinsonism and other Gaucher-related synucleinopathies. Proc Natl Acad Sci USA. 2013;110:3537–3542. - PMC - PubMed
    1. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher’s disease. Lancet. 2008;372(9645):1263–1271. - PubMed
    1. Ron I, Horowitz M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum Mol Genet. 2005;14(16):2387–2398. - PubMed
    1. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson disease: Implications for treatment. Nat Rev Neurol. 2010;6(6):309–317. - PubMed
    1. Sidransky E, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson’s disease. N Engl J Med. 2009;361(17):1651–1661. - PMC - PubMed

Publication types